Ultragenyx to Participate at Investor Conferences in London
Key Highlights
- ➤Ultragenyx executives will participate in UBS Global Biopharma Conference 2026 on November 16
- ➤Ultragenyx executives will participate in Jefferies Global Healthcare Conference on November 17
- ➤Fireside chats and 1x1 investor meetings are scheduled at both conferences
NOVATO, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced participation in upcoming investor conferences.
UBS Global Biopharma Conference 2026 * Monday, November 16, 2026, Emil Kakkis, M.D., Ph.D., President and Chief Executive Officer, Eric Crombez, M.D., Chief Medical Officer, and Howard Horn, Chief Financial Officer, will participate in a fireside chat and host 1x1 meetings. 2026 Jefferies Global Healthcare Conference * Tuesday, November 17, 2026, Emil Kakkis, Eric Crombez, and Howard Horn will participate in a fireside chat and host 1x1 meetings. The live and archived webcast of the fireside chat will be accessible from the company’s website at https://ir.ultragenyx.com/events-presentations.
Get started
Create a free account to read the full story.